<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04204434</url>
  </required_header>
  <id_info>
    <org_study_id>Biomarkers For I.C. Inhibitors</org_study_id>
    <nct_id>NCT04204434</nct_id>
  </id_info>
  <brief_title>Biomarkers For Immune Checkpoint Inhibitors</brief_title>
  <official_title>Biomarkers For Immune Checkpoint Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rhode Island Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a laboratory, non-treatment study. Immune checkpoint inhibitors are a type of
      immunotherapy that stimulates a patients immune system to fight their cancer. Immune
      checkpoint inhibitors are standard, FDA approved treatment for certain types of cancers such
      as melanoma, lung cancer, kidney cancer and bladder cancer. The laboratories of Dr. Jack
      Elias and Dr. Chun Geun Lee at Brown University are studying how immune checkpoint inhibitors
      work.Kintai Therapeutics is a biotech company in Cambridge Massachusetts that will focus on
      the molecules present in the GI tract, including the stomach, small intestine and colon.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are receiving immune checkpoint inhibitors for their cancer treatment are
      eligible. Patients will sign informed consent. Ten cc of blood will be drawn before beginning
      immune checkpoint inhibitors and 10 cc of blood will be drawn 1-4 months after treatment is
      initiated. Deidentitified blood samples will be sent to the lab of Dr. Jack Elias and Dr.
      Chun Geul Lee and analyzed for biomarkers. The blood samples will be linked to the patient by
      a research number. Response to treatment will be correlated to potential biomarkers. The
      stool samples will be linked to the patient by a research number. Bacterial DNA and RNA may
      be sequenced and data used to identify bacterial taxa and genes within the stool. In
      compliance with NIH guidelines, all human DNA data would be removed computationally, and will
      not be used in any analyses. Small molecules may be profiled with metabolomics. Bacteria may
      also be isolated from the stool into in vitro culture, and efficacy of single-strains or
      communities and/or their DNA, RNA, and metabolites on disease models may be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2016</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>To determine serum predictors of response to immune checkpoint inhibitors at study entry, prior to checkpoint inhibitor therapy</measure>
    <time_frame>At study entry, prior to checkpoint inhibitor therapy Anytime between 6-12 weeks after initiating treatment.</time_frame>
    <description>Measure biomarker levels of immune checkpoint inhibitors in blood serum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine serum predictors of response to immune checkpoint inhibitors 4-weeks after initiation of treatment</measure>
    <time_frame>Within 4 weeks after initiation of treatment</time_frame>
    <description>Measure biomarker levels of immune checkpoint inhibitorsin blood serum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine serum predictors of response to immune checkpoint inhibitors anytime between 6-12 weeks after initiating treatment.</measure>
    <time_frame>6-12 weeks after initiating treatment</time_frame>
    <description>Measure biomarker levels of immune checkpoint inhibitors in blood serum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate bacteria, and bacterial products in gut microbiome before and after treatment with immune checkpoint inhibitors and correlate to response and toxicity.</measure>
    <time_frame>At study entry, prior to immune checkpoint inhibitor therapy</time_frame>
    <description>Measure bacteria and bacterial products in gut micobiome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate bacteria, and bacterial products in gut microbiome before and after treatment with immune checkpoint inhibitors and correlate to response and toxicity.</measure>
    <time_frame>Within 4 weeks after initiation of treatment</time_frame>
    <description>Measure bacteria and bacterial products in gut micobiome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate bacteria, and bacterial products in gut microbiome before and after treatment with immune checkpoint inhibitors and correlate to response and toxicity.</measure>
    <time_frame>Anytime between 6-12 weeks after initiating treatment.</time_frame>
    <description>Measure bacteria and bacterial products in gut micobiome</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Advanced Cancer</condition>
  <condition>Neoplasms</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool, tissue, blood, and plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with an advanced solid cancer prior to initiating treatment with an
        immune checkpoint inhibitor are eligible.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with advanced solid tumors initiating treatment with an immune checkpoint
             inhibitor.

          -  No prior immune checkpoint inhibitors

          -  Age &gt;18.

          -  Signed informed consent

        Exclusion Criteria:

          -  The patient is unwilling or unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Safran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rhode Island Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Schumacher, MSHCE</last_name>
    <phone>401-444-3234</phone>
    <email>aschumacher@lifespan.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alise K Lombardo, BS, CCRP</last_name>
    <phone>401-444-8856</phone>
    <email>alombardo@lifespan.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Schumacher, MSHCE</last_name>
      <phone>401-444-3234</phone>
      <email>aschumacher@lifespan.org</email>
    </contact>
    <contact_backup>
      <last_name>Alise Lombardo, BS</last_name>
      <phone>401-444-8856</phone>
      <email>alombardo@lifespan.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Schumacher, MSHCE</last_name>
      <phone>401-444-3234</phone>
      <email>aschumacher@lifespan.org</email>
    </contact>
    <contact_backup>
      <last_name>Alise Lombardo, BS</last_name>
      <phone>401-444-8856</phone>
      <email>alombardo@lifespan.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci. 2011 Jan;1217:45-59. doi: 10.1111/j.1749-6632.2010.05919.x. Review.</citation>
    <PMID>21276005</PMID>
  </reference>
  <reference>
    <citation>Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009 May;229(1):114-25. doi: 10.1111/j.1600-065X.2009.00767.x. Review.</citation>
    <PMID>19426218</PMID>
  </reference>
  <reference>
    <citation>Doi T, Piha-Paul SA, Jalal SI, et al. Pembrolizumab (MK-3475) for patients with advanced esophageal carcinoma: Preliminary results from KEYNOTE-028.J Clin Oncol 33, 2015 (suppl; abstr 4010).</citation>
  </reference>
  <reference>
    <citation>Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11;369(2):134-44. doi: 10.1056/NEJMoa1305133. Epub 2013 Jun 2. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.</citation>
    <PMID>23724846</PMID>
  </reference>
  <reference>
    <citation>Le D, Bendell JC, Calvo E, et al. Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study. J Clin Oncol 34; 2016 (supp; abstr 06).</citation>
  </reference>
  <reference>
    <citation>Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial. J Clin Oncol 32:5s, 2014 (suppl; abstr 5009).</citation>
  </reference>
  <reference>
    <citation>Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, Gergich K, Delgado L, Daud A, Lindia JA, Li XN, Pierce RH, Yearley JH, Wu D, Laterza O, Lehnert M, Iannone R, Tolcher AW. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2015 Oct 1;21(19):4286-93. doi: 10.1158/1078-0432.CCR-14-2607. Epub 2015 May 14.</citation>
    <PMID>25977344</PMID>
  </reference>
  <reference>
    <citation>Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.</citation>
    <PMID>22658127</PMID>
  </reference>
  <reference>
    <citation>Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.</citation>
    <PMID>26028407</PMID>
  </reference>
  <reference>
    <citation>Durham NM, Nirschl CJ, Jackson CM, Elias J, Kochel CM, Anders RA, Drake CG. Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. PLoS One. 2014 Nov 5;9(11):e109080. doi: 10.1371/journal.pone.0109080. eCollection 2014.</citation>
    <PMID>25372844</PMID>
  </reference>
  <results_reference>
    <citation>Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001 Mar;2(3):261-8.</citation>
    <PMID>11224527</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Advanced</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Advanced Solid Tumor</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

